{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:08:56Z","timestamp":1773706136815,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"am","delay-in-days":419,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12CA226330"],"award-info":[{"award-number":["K12CA226330"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.transci.2023.103731","type":"journal-article","created":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T19:19:48Z","timestamp":1684610388000},"page":"103731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cryopreservation and storage patterns of hematopoietic progenitor stem cells for multiple myeloma"],"prefix":"10.1016","volume":"62","author":[{"given":"Cara L.","family":"Benjamin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreena","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amer","family":"Beitinjaneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lazaros","family":"Lekakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishna V.","family":"Komanduri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trent P.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2023.103731_bib1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current status of autologous stem cell transplantation for multiple myeloma","volume":"9","author":"Al Hamed","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.transci.2023.103731_bib2","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.bbmt.2013.08.002","article-title":"Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma","volume":"19","author":"Costa","year":"2013","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.transci.2023.103731_bib3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2023.103731_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2020.102785","article-title":"New horizons on stem cell cryopreservation through the artificial eyes of Cd 34+, using modern flow cytometry tools","volume":"59","author":"Lanza","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2023.103731_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2020.102753","article-title":"Manipulation, and cryopreservation of autologous peripheral blood stem cell products in Italy: a survey by GITMO, SIDEM and GIIMA societies","volume":"59","author":"Lanza","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2023.103731_bib6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/bmt.2015.13","article-title":"Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy","volume":"50","author":"Phipps","year":"2015","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2023.103731_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jca.21556","article-title":"Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation","volume":"33","author":"Moreb","year":"2018","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2023.103731_bib8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.bmt.1701828","article-title":"Collection of peripheral blood stem cells after a preceding autograft: unfavorable effect of prior interferon-alpha therapy","volume":"24","author":"Singhal","year":"1999","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2023.103731_bib9","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2023.103731_bib10","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2023.103731_bib11","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2023.103731_bib12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2023.103731_bib13","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/bmt.2015.83","article-title":"Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2023.103731_bib14","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1600-0609.2011.01605.x","article-title":"Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells","volume":"86","author":"Basak","year":"2011","journal-title":"Eur J Haematol"},{"issue":"244","key":"10.1016\/j.transci.2023.103731_bib15","article-title":"Low-dose cyclophosphamide versus intermediate-high-dose cyclophosphamide versus granulocyte colony-stimulating factor alone for stem cell mobilization in multiple myeloma in the era of novel agents: a multicenter retrospective study","volume":"27","author":"Zannetti","year":"2021","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.transci.2023.103731_bib16","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2023.103731_bib17","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial","volume":"8","author":"Diamond","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.transci.2023.103731_bib18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/bjh.12579","article-title":"Second autologous transplant as salvage therapy in multiple myeloma","volume":"163","author":"Atanackovic","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2023.103731_bib19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5045\/br.2017.52.4.307","article-title":"Is long term storage of cryopreserved stem cells for hematopoietic stem cell transplantation a worthwhile exercise in developing countries?","volume":"52","author":"Devadas","year":"2017","journal-title":"Blood Res"},{"key":"10.1016\/j.transci.2023.103731_bib20","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.bbmt.2020.04.030","article-title":"Storage, utilization, and disposal of hematopoietic stem cell products in patients with multiple myeloma","volume":"26","author":"Krummradt","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.transci.2023.103731_bib21","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.3109\/10428194.2012.751528","article-title":"Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma","volume":"54","author":"Dunavin","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.transci.2023.103731_bib22","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2023.103731_bib23","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.bbmt.2020.07.019","article-title":"Utilization and cost implications of hematopoietic progenitor cells stored for a future salvage autologous transplantation or stem cell boost in myeloma patients","volume":"26","author":"Chhabra","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.transci.2023.103731_bib24","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.bbmt.2018.04.007","article-title":"Analysis of clinical factors and outcomes associated with nonuse of collected peripheral blood stem cells for autologous stem cell transplants in transplant-eligible patients with multiple myeloma","volume":"24","author":"Kansagra","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.transci.2023.103731_bib25","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5500\/wjt.v7.i5.250","article-title":"Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?","volume":"7","author":"Wallis","year":"2017","journal-title":"World J Transpl"},{"key":"10.1016\/j.transci.2023.103731_bib26","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/jca.21885","article-title":"Stem cell mobilization in multiple myeloma patients relapsing after previous autologous hematopoietic stem cell transplantation: a multicenter report by the Polish Myeloma Study Group","volume":"36","author":"Drozd-Sokolowska","year":"2021","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2023.103731_bib27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.bmt.1705908","article-title":"AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and\/or cytokine treatment: compassionate use data","volume":"41","author":"Calandra","year":"2008","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2023.103731_bib28","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/10428194.2019.1697814","article-title":"Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)","volume":"61","author":"Nahas","year":"2020","journal-title":"Leuk Lymphoma"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050223001052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050223001052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:56:36Z","timestamp":1761468996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050223001052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1473050223001052"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2023.103731","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cryopreservation and storage patterns of hematopoietic progenitor stem cells for multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2023.103731","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103731"}}